Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia 1Head and Neck Neoplasms 1Adenocarcinoma of Lung 1

Interventions

fludarabine 9Cytarabine 9venetoclax 5fludarabine phosphate 5Cyclophosphamide 5Busulfan 5thymoglobulin 4Tacrolimus 4Sirolimus 4Mycophenolic Acid 4Methotrexate 4Azacitidine 4aldesleukin 3Whole-Body Irradiation 3Interleukin-2 3Antilymphocyte Serum 3asciminib 2Thiotepa 2Peripheral Blood Stem Cell Transplantation 2Mitoxantrone 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Dasatinib 2Cyclosporine 2Bone Marrow Transplantation 2Blood Specimen Collection 2Behavior Therapy 2zileuton 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myeloid × zileuton × Clear all
NCT02047149 2016-09-30

Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia

University of Massachusetts, Worcester

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡